Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Microbiome
L’Oréal and Micreos target skin bacteria
by Melody M. Bomgardner
November 8, 2020
| A version of this story appeared in
Volume 98, Issue 43
The cosmetics maker L’Oréal will license an endolysin enzyme developed by Dutch firm Micreos for use in microbiome-friendly skin-care products. The firms say the enzyme targets bacteria responsible for conditions such as inflammatory acne but, unlike antibiotics, does not harm beneficial bacteria. L’Oréal says the deal is part of its 15-year effort to better understand the role of the skin microbiome. Micreos is developing another endolysin as a pharmaceutical to treat atopic dermatitis.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X